Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovagin... (ls (which indicate a wellestrogenized ef...)

HOME >> MEDICINE >> TECHNOLOGY

Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy

Date:6/16/2008

ls (which indicate a well estrogenized effect) as compared to two percent with placebo. The decrease in pH to a more favorable one in the treatment group was also statistically significant as compared to placebo (-1.01 1.1 versus -0.10 0.8). Ophena(TM) was generally well tolerated and demonstrated a favorable safety profile.

Ophena(TM), a novel selective estrogen receptor modulator (SERM), is being studied as a non-estrogen alternative for the treatment of symptoms of postmenopausal vaginal syndrome (PVS), also known as vaginal atrophy. The only FDA approved prescription products currently available to treat PVS contain estrogen. Treatment with estrogen therapy has been associated with certain health risks, and many women prefer non-estrogen alternatives.

"These results provide strong support for our efforts to advance Ophena(TM) through the regulatory review process. Our next Phase 3 trial for Ophena(TM) will begin later this year. We remain committed to completing the necessary clinical studies and regulatory filings in support of Ophena(TM) as quickly as possible to make this non-estrogen treatment option available to the millions of women affected by vulvovaginal atrophy around the world" added Robert Zerbe, M.D.

About Postmenopausal Vaginal Syndrome

Postmenopausal vaginal syndrome (PVS) is a chronic and progressive condition characterized by symptoms including vaginal dryness, sexual pain (dyspareunia) and irritation. Declining estrogen levels during menopause can cause tissues of the vaginal lining to grow thinner and to lose elasticity, a condition known as atrophy. Dryness and irritation associated with reductions in vaginal secretions often cause pain or bleeding during sexual intercourse. It is estimated that up to 45-75 percent of post-menopausal women have chronic symptoms of PVS. Current prescription treatments approved for this condition all contain estrogen, administered either orally or locally in the vagina. SERMs that
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4
Related medicine technology :

1. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
6. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
9. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
10. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
11. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)

Post Your Comments:

(Date:12/15/2009)... Genomic Health, Inc. (Nasdaq: GHDX ) ... Onco type DX® breast cancer test, a multi-gene ... likelihood of chemotherapy benefit and recurrence risk for patients ... the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, ... TX. ,, "The breadth of data presented at last ...

(Date:12/15/2009)... Arlington Medical Resources (AMR) and Decision ... (MRSA) is the most concerning pathogen to surveyed ... treatment of skin and skin structure infections. A ... factors that influences European physician drug selection for ... factors that drive prescribing include an agent,s skin ...

(Date:12/15/2009)... INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 15 ... ), Eli Lilly and Company (NYSE: ... ) today announced positive results from a head-to-head ... therapy, to BYETTA® (exenatide) injection taken twice daily, ... weeks of treatment, patients taking exenatide once weekly ...

Breaking Medicine Technology:Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 2 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 3 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 4 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 5 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 6 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 7 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 2 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 3 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7 Study Forecasts More Young Doctors in Future 59852 1 Study Forecasts More Young Doctors in Future 59852 2 Experimental treatments restore partial vision to blind people 10444 1 Experimental treatments restore partial vision to blind people 10444 2 Minnesota Dentists Warn Halloween Shoppers 3A Sour Candies May Trick Not Treat Teeth 59846 1 Minnesota Dentists Warn Halloween Shoppers 3A Sour Candies May Trick Not Treat Teeth 59846 2

[0] Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations [0] A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections [0] Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study

... Drugs on the Market and, in Clinical Development with Each ... Anticancer Effects, and Expand the Markets for ... ... Identification of novel,cancer-related targets and pathways is redefining our understanding of ...

... Mich., Feb. 19 Compendia Bioscience, Inc.,today announced ... renewed,and expanding commitment from all major customers and ... to its customer roster. The new,customers and existing ... revenue increase, with similar growth forecasted for 2008., ...

Other Medicine Technology:Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 2 Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 3 Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 4 On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments 2 On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments 3

Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments

(Date:12/14/2009)... Adults, Attitudes and Behavior Regarding Pregnancy, Contraception, and Related ... Nearly all unmarried young adults ages 18-29 believe pregnancy ... and 86% of women) and say that it is ... (86% of men and 88% of women), according to ... Teen and Unplanned Pregnancy. Even so: ,, ...

(Date:12/14/2009)... oxygen, drugs, and more… , ... ... in collaboration with scientists at University of Michigan, have developed ... of natural red blood cells, including softness, flexibility, and the ... primary function of natural red blood cells is to carry ...

(Date:12/14/2009)... ARBOR, Mich., Dec. 14 Pepsi ... the Commonwealth of Kentucky are among the major ... this fall to help their employees make better ... solution gives employees a personalized summary of their ... of that care. With this personalized information, employees ...

(Date:12/14/2009)... -- Americold Realty Trust ("Americold") announced today that it ... the U.S. Securities and Exchange Commission (the "SEC") relating ... shares. The number of shares to be offered and ... been determined. The common shares to be sold in ... ,, The joint book-running managers of the offering ...

(Date:12/14/2009)... BRAINTREE, Mass., Dec. 14 Haemonetics Corporation ... it has filed a new legal action to ... Fenwal,s just released red cell collection kits, using ... its separation chamber to circumvent Haemonetics, patent and ... continued sale of infringing products after December 1, ...

Breaking Medicine News(10 mins):Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2 Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3 Health News:Synthetic Red Blood Cells Developed 2 Health News:Synthetic Red Blood Cells Developed 3 Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2 Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2 Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2 Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3

[1] Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference [0] Synthetic Red Blood Cells Developed [0] Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process [0] Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering [0] Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement

... SAN DIEGO, Nov. 24 Volcano Corporation (Nasdaq: VOLC ... for the diagnosis and treatment of coronary and peripheral artery disease, ... Piper Jaffray Health Care Conference on Tuesday, December 2. , ... and chief executive officer, will begin at 1:30 p.m., Eastern Standard ...

... Calif., Nov. 24 Thoratec Corporation,(Nasdaq: THOR ... to save, support and restore falling hearts, said today ... Jaffray Heath Care Conference on,Wednesday, December 3. , ... provide an,update on the company, beginning at 1 p.m., ...

... Networks, Inc.(TM), the,company delivering new technology in enterprise ... Networks executive Amit Chawla as its new President,and ... Agito Networks, flagship product is the ... IP telephony, and,location information, improving the accessibility and ...

... Leading Specialty Pharmaceutical Company with Greater Commercialization Capabilities, Expanded Portfolio of ... , King Extends Tender Offer Through December 19, 2008 ... BRIDGEWATER, N.J., Nov. 24 King Pharmaceuticals, Inc. (NYSE: ... announced that the two companies have signed a definitive merger agreement ...

... with Broad Potential to Treat Life-Threatening Viral Infections-- , ... and Equivalent Antibodies Cured Lethal Viral Infections in Preclinical Models-- ... is a ,Druggable, Target Common to a Number of Serious ... Calif., Nov. 24 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) ...

... summarized- , , ... Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian ... Cell Wall-DNA Complex (MCC) - trademarked Urocidin - ... 2008 Societe Internationale d,Urologie (SIU) Congress in Santiago, ...

Volcano Corporation Presentation at Piper Jaffray Conference to Be Webcast Thoratec Presentation at Piper Jaffary Conference to be Webcast Agito Networks Names New CEO, Broadens Depth of Experience of Enterprise Mobility Leader King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile

For the quantitative determination of uric acid in serum....

... new level of immunodiagnostic productivity. Optimal flexibility. ... laboratory automation system. No-pause loading of all ... only immunoassay system with this capability. No ... without any additional setup. Continuous sample loading. ...

... Engineered for continuous, random access operation, the ... medium to large volume laboratories that want ... offers the simplicity, flexibility and Stat capabilities ... can be adapted to the changing needs ...

The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...

Medicine Products:

Uric Acid Reagent Set Advia Centaur Elecsys 2010 Disk System Dimension RxL Max w/o HM 50/60 HZ

Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovagin...(ls (which indicate a wellestrogenized ef...),Health